VOR Vor Bio, Inc.

NASDAQ
$18.52

Vor Bio, Inc. (VOR) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.81 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.8% since its last earnings release on August 11, 2026.

Vor Bio Missed Consensus Estimates
Tuesday, August 11, 2026 · 9:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 9:30 AM ET
Earnings Whisper
-
vs ($0.81)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $22.43

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vor Bio, Inc.

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.